Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus NEBCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN versus NEBCIN.
BACITRACIN-NEOMYCIN-POLYMYXIN vs NEBCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Apply topically to affected area 2-5 times daily.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
None Documented
None Documented
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic